Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (NASDAQ: BNGO) regularly issues news and updates about its genome analysis technologies, financial results and scientific collaborations. The company describes itself as a provider of optical genome mapping (OGM) solutions, diagnostic services and software that support research and clinical research applications in areas such as inherited disease, reproductive disorders, hematologic malignancies, solid tumors and rare diseases.
On this page, readers can follow Bionano’s announcements about quarterly and annual financial results, capital markets transactions, and strategic shifts in its business model. Recent press releases have discussed the company’s focus on routine users of its OGM solutions, trends in consumables and software utilization, and public offerings of common stock and warrants disclosed through SEC filings and corresponding news releases.
Bionano’s news flow also highlights scientific and clinical research progress involving OGM. The company frequently reports on studies presented at major conferences such as the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP), where researchers have described OGM’s use in detecting structural variants across a range of genetic conditions. In addition, Bionano has drawn attention to peer-reviewed publications, including work from The University of Texas MD Anderson Cancer Center comparing OGM with targeted RNA-sequencing in acute leukemia.
Updates from Bionano Laboratories, the company’s CLIA-certified laboratory business, cover developments in OGM-based laboratory developed tests and reimbursement, including Category I CPT codes 81195 and 81354 for OGM applications in hematologic malignancies and constitutional genetic disease. Investors and researchers can use this news page to review BNGO’s historical and ongoing disclosures about its technology platforms, research collaborations, reimbursement milestones and financial performance.
Bionano Genomics (NASDAQ: BNGO) has announced its active participation in the 2024 European Society for Human Genetics (ESHG) Annual Conference and the 2024 American Cytogenomics Conference (ACC), featuring 39 scientific presentations and posters.
These contributions will demonstrate the application of Bionano's Optical Genome Mapping (OGM) in genetic disorder, rare disease, and cancer research. Highlights include a session at ESHG presenting the OGM workflow, innovations such as the Stratys system and VIA software, and case studies on hereditary angioedema, structural variants in rare diseases, and multiple myeloma.
Key presentations at ACC will focus on OGM's role in enhancing detection of pathogenic variants and advancing genetic disease research. The sessions will cover the latest updates in the OGM workflow, aiming to improve sample-to-answer time and structural variant detection.
Bionano Genomics (NASDAQ: BNGO) announced a private placement of senior secured convertible debentures due May 24, 2026, raising $18 million.
This financing will retire previous convertible debt from October 2023 and February 2024, strengthening the company's capital structure, liquidity, and ability to drive adoption of optical genome mapping while reviewing strategic alternatives to maximize shareholder value.
Canaccord Genuity acted as an exclusive financial advisor and placement agent for the offering. The securities were not registered under the Securities Act and are restricted from public offering within the United States.
Bionano Genomics, stock symbol BNGO, announced three new studies that support the use of Optical Genome Mapping (OGM) in cell and gene therapy development. These studies demonstrate OGM's ability to detect genome integrity and structural variations in therapeutic cell lines like CAR-T cells, stem cells, and hiPSCs. The first study from Niño Jesús University Children's Hospital showed OGM's efficacy in assessing genotoxicity in CAR-T cells. The second study from Ruhr-University Bochum demonstrated OGM's utility in evaluating genome integrity post-CRISPR/Cas9 editing for Alzheimer's research. The third study from Janssen explored OGM's role in confirming the absence of off-target effects in stem cells edited for the APOE genotype, associated with Alzheimer's disease.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. The enhancements to the VIA™ software solution improve the detection and interpretation of aneusomies, small structural variants, and copy number variants. The upgrades also include dynamic visualization tools for better representation of findings, automated analysis, and interpretation of variants, and standardized Phred scale calculation for SV confidence scores.
Bionano Genomics, Inc. (BNGO) reported Q1 2024 revenue of $8.8 million, an 18% increase over Q1 2023. The company's total installed base of optical genome mapping systems grew by 34%, with 8,249 nanochannel array flowcells sold, a 58% increase. BNGO announced a partnership with Hangzhou Diagens Biotechnology, a direct offering of $10 million, and planned software enhancements for cancer analysis. The company reiterated full-year revenue guidance of $37.0 to $41.0 million for 2024.
Bionano Genomics, Inc. (Nasdaq: BNGO) will report its first quarter 2024 financial results on May 8, 2024, with a conference call and webcast to discuss recent corporate progress. Participants can join the event via phone or webcast and access a replay on the company's investor relations website.
Bionano Genomics, Inc. will present at the RBC Capital Markets 2024 Global Healthcare Conference, with Erik Holmlin, PhD, as the presenter. The conference will take place on May 15, 2024, and a replay will be available on the Bionano website.
Summary not available.
Summary not available.
Summary not available.